Veterinary Medicines

Bravecto 150 mg/ml - Powder and solvent for suspension for injection

Authorised
  • Fluralaner
Download as PDF

Product identification

Medicine name:
Bravecto 150 mg/ml - Powder and solvent for suspension for injection
Active substance:
  • Fluralaner
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Fluralaner
    150.00
    milligram(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Powder and solvent for suspension for injection
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP53BE02
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Latvia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)
Available in:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)
Package description:
  • Packaging:Vial (glass), Package_size:1 vial of powder + 1 vial of solvent, 1 vent needle
  • Packaging:Vial (glass), Package_size:2 vials of powder + 2 vials of solvent, 2 vent needles
  • Packaging:Vial (glass), Package_size:10 vials of powder + 10 vials of solvent, 10 vent needles
  • Packaging:Vial (glass), Package_size:5 vials of powder + 5 vials of solvent, 5 vent needles

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Intervet International B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Intervet GesmbH
  • Intervet Productions S.A.
  • Vet Pharma Friesoythe GmbH
Responsible authority:
  • European Commission
Authorisation number:
This information is not available for this product.
Date of authorisation status change:

Documents

Combined File of all Documents

English (PDF)
Published on: 28/07/2025
Download
Bulgarian (PDF)
Published on: 28/07/2025
Download
Croatian (PDF)
Published on: 28/07/2025
Download
Czech (PDF)
Published on: 28/07/2025
Download
Danish (PDF)
Published on: 28/07/2025
Download
Dutch (PDF)
Published on: 28/07/2025
Download
Estonian (PDF)
Published on: 28/07/2025
Download
Finnish (PDF)
Published on: 28/07/2025
Download
French (PDF)
Published on: 28/07/2025
Download
German (PDF)
Published on: 28/07/2025
Download
Greek (PDF)
Published on: 28/07/2025
Download
Hungarian (PDF)
Published on: 28/07/2025
Download
Icelandic (PDF)
Published on: 28/07/2025
Download
Italian (PDF)
Published on: 28/07/2025
Download
Latvian (PDF)
Published on: 28/07/2025
Download
Lithuanian (PDF)
Published on: 28/07/2025
Download
Maltese (PDF)
Published on: 28/07/2025
Download
Norwegian (PDF)
Published on: 28/07/2025
Download
Polish (PDF)
Published on: 28/07/2025
Download
Portuguese (PDF)
Published on: 28/07/2025
Download
Romanian (PDF)
Published on: 28/07/2025
Download
Slovak (PDF)
Published on: 28/07/2025
Download
Slovenian (PDF)
Published on: 28/07/2025
Download
Spanish (PDF)
Published on: 28/07/2025
Download
Swedish (PDF)
Published on: 28/07/2025
Download

ema-puar-v2526-bravecto-vra0059-en.pdf

English (PDF)
Published on: 23/05/2024
Download